EUVIMEDEUVIMED entdecken
Crossref

Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis

Gustavo Drügg Hahn iD, Peter Laszlo Lakatos, Chelsea Maedler-Kron, Victoria Marcus, Waqqas Afif iD, Gary Wild iD, Alain Bitton, Cristina Flores, Carlos Fernando de Magalhães Francesconi iD, Talat Bessissow iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Gustavo Drügg Hahn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Colitis, Ulcerative, Feces. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fecal calprotectin is a reliable surrogate marker for disease activity in ulcerative colitis. However, there are no consensus cutoff values for histoendoscopic remission. This study aimed to correlate fecal calprotectin with Mayo endoscopic score and histological disease activity (Geboes score) for ulcerative colitis patients in clinical remission.

Methods

Prospective study including adult ulcerative colitis patients in clinical remission or disease relapse, undergoing endoscopy for disease activity or dysplasia surveillance at an inflammatory bowel disease center between 2013 and 2020. Fecal calprotectin was collected before bowel preparation and Mayo endoscopic score was documented during colonoscopy. Biopsies were taken throughout the colon and histological activity was assessed using Geboes score by a blinded expert gastrointestinal pathologist.

Results

Two hundred fifty-three patients were included, 117 (46%) were male (mean age of 38.2 years—standard deviation ± 24.8). A fecal calprotectin ≥ 123 μg/g predicts Mayo endoscopic score > 0 (58% sensitivity and 70% specificity), also aiding to differentiate Mayo endoscopic score 0 from 1 (61% sensitivity and 70% specificity). A fecal calprotectin ≥ 80 μg/g identified histological disease activity using Geboes score > 3.1 in patients with clinical remission (64.7% sensitivity, 58.7% specificity). Using Geboes score > 2, a fecal calprotectin ≥ 50 μg/g, is the most clinically relevant to identify patients in clinical remission with active histologic inflammation (49.6% sensitivity, 41.6% specificity).

Conclusions

Fecal calprotectin correlates with endoscopic and histologic disease activity and can be used as a surrogate marker for disease activity. Our study prospectively demonstrated optimal cutoff values to discriminate histoendoscopic remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexColitis, UlcerativeFecesHumansMaleAdultFemaleProspective StudiesColonoscopyMiddle AgedRemission InductionBiomarkersSeverity of Illness IndexBiopsyYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

endoscopic remissionfecal calprotectinhistologic remissionulcerative colitis

Substanzen

Leukocyte L1 Antigen ComplexBiomarkers

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, McGill University, Montreal, QC, Canada.
  • Graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Department of Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • First Department of Medicine, Semmelweis University, Budapest, Hungary.
  • Department of Pathology, McGill University Health Center, Montreal, QC, Canada.
  • Diimuno - Center for treatment of Inflammatory Bowel Diseases and Immune-mediated Diseases, Porto Alegre, RS, Brazil.

ORCID-Profile: Gustavo Drügg Hahn, Waqqas Afif, Gary Wild, Carlos Fernando de Magalhães Francesconi, Talat Bessissow

Zitieren

APA

Drügg Hahn, G., Lakatos, P. L., Maedler-Kron, C., Marcus, V., Afif, W., Wild, G., Bitton, A., Flores, C., de Magalhães Francesconi, C. F., & Bessissow, T. (2025). Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf008

Vancouver

Drügg Hahn G, Lakatos PL, Maedler-Kron C, Marcus V, Afif W, Wild G, et al. Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf008

BibTeX
@article{DrggHahn2025,
  author = {Drügg Hahn, Gustavo and Lakatos, Peter Laszlo and Maedler-Kron, Chelsea and Marcus, Victoria and Afif, Waqqas and Wild, Gary and Bitton, Alain and Flores, Cristina and de Magalhães Francesconi, Carlos Fernando and Bessissow, Talat},
  title = {Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf008}
}
Kostenlos starten →